Using Human 'Personalized' Cybrids to Identify Drugs/Agents That Can Regulate Chronic Lymphoblastic Leukemia...

Area of Science:

• Cell Biology
• Oncology
• Pharmacology

Background:

• Chronic lymphoblastic leukemia (CLL) is a B-cell malignancy characterized by mitochondrial dysfunction.
• Ibrutinib is a targeted therapy for CLL, but its efficacy can be limited.
• Mitochondrial-targeted nutraceuticals are being explored for their potential therapeutic benefits.

Purpose of the Study:

• To investigate the effects of combining ibrutinib with nutraceuticals on CLL cybrid cells.
• To assess the impact of these combinations on mitochondrial function, cell survival, and apoptosis.

Main Methods:

• Personalized chronic lymphoblastic leukemia (CLL) cybrid cells were treated with ibrutinib, alpha lipoic acid, amla, melatonin, or resveratrol, alone and in combination.
• Cellular metabolism, intracellular ROS levels, and mitochondrial membrane potential (∆ψm) were measured using MTT, H2DCFDA, and JC1 assays.
• Gene expression of antioxidant, apoptotic, and inflammatory markers was analyzed via quantitative real-time PCR (qRT-PCR).

Main Results:

• Combination treatments (Ibrutinib + Nutraceuticals) resulted in reduced cell survivability and increased ROS production in CLL cybrids.
• Enhanced mitochondrial membrane potential (∆ψm) and decreased expression of antioxidant genes were observed with combination therapies.
• Apoptotic and inflammatory gene expression significantly increased in CLL cybrids treated with ibrutinib plus nutraceuticals compared to ibrutinib alone.

Conclusions:

• The addition of nutraceuticals to ibrutinib therapy potentiates pro-apoptotic effects in CLL cybrid cells.
• Combination therapy leads to decreased cell survival compared to ibrutinib monotherapy.
• These findings suggest a potential synergistic role for nutraceuticals in enhancing ibrutinib efficacy for CLL treatment.